Published in Pharma Law Weekly, December 29th, 2009
According to the INS publication: "In September 2007, the FDA approved the first anthracycline extravasation treatment, Totect (dexrazoxane for injection), which has a 98% efficacy in diminishing tissue damage and allows the majority of patients to continue with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly